Biofil Chemicals & Pharmaceuticals Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹51 Cr
- P/E
- 98.21
- ROE
- -2.83%
- Price to sales
- 2.27
- Debt to equity
- 0.10
- 52W high / low
- ₹47.7 / ₹25.8
- Sales growth (5Y)
- -4.50%
- EBITDA margin
- 3.39%
- Net profit margin
- -2.01%
- Promoter holding
- 46.79%
- Sales (last year)
- ₹22 Cr
Incorporated in 1993, Biofil Chemicals and Pharmaceuticals Ltd manufactures pharmaceutical bulk drugs[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Biofil Chemicals & Pharmaceuticals latest results (Sep 2026)
Revenue
₹2 Cr
-87.67% YoY
Net profit
₹0 Cr
+50% YoY
Operating margin
5.99%
EPS
₹0.07
Biofil Chemicals & Pharmaceuticals shareholding (Sep 2026)
Promoters
46.79%
unchanged QoQ
FIIs
0.00%
unchanged QoQ
DIIs
0.08%
unchanged QoQ
Public
53.13%
unchanged QoQ
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹3,041 Cr | 33.1 | |
| 2 | 40%+ | Up 2%+ | ₹492 Cr | 19.6 | |
| 3 | 40%+ | Up 0–2% | ₹234 Cr | 17.8 | |
| 4 | 40%+ | Flat | ₹18,347 Cr | — | |
| 5 | 40%+ | Flat | ₹8,432 Cr | 32.4 | |
| 6 | 40%+ | Flat | ₹4,295 Cr | — |
Sign up free to see every company in the sector ranking and track Biofil Chemicals.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Biofil Chemicals
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Biofil Chemicals
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 46.82% | 46.82% | 46.82% | 46.82% | 46.82% | 46.82% | 46.82% | 46.79% | 46.79% | 46.79% | 46.79% | 46.79% |
| FIIs + | 0.00% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DIIs + | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% | 0.08% |
| Public + | 53.11% | 53.08% | 53.11% | 53.10% | 53.11% | 53.11% | 53.10% | 53.12% | 53.13% | 53.12% | 53.13% | 53.13% |
| No. of Shareholders | 25,864 | 26,581 | 25,480 | 26,422 | 26,114 | 25,914 | 25,685 | 25,196 | 24,825 | 25,356 | 24,999 | 24,660 |
Pros & Cons
Biofil Chemicals
Key positives and risks surfaced from the company insights section.
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -4.50% over past five years.
- Company has a low return on equity of 1.24% over last 3 years.
- Earnings include an other income of Rs.0.38 Cr.
- Company has high debtors of 355 days.
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -4.50% over past five years.
- Company has a low return on equity of 1.24% over last 3 years.
- Earnings include an other income of Rs.0.38 Cr.
- Company has high debtors of 355 days.
Financials of Biofil Chemicals
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 17.37 | 5.03 | 15.20 | 8.44 | 2.41 | 14.20 | 8.35 | 6.43 | 13.54 | 0.86 | 7.57 | 12.35 | 1.67 |
| YoY Sales growth | +562.98% | +237.58% | +11.60% | +247.33% | -86.13% | +182.31% | -45.07% | -23.82% | +461.83% | -93.94% | -9.34% | +92.07% | -87.67% |
| Expenses + | 17.13 | 4.84 | 15.24 | 8.13 | 2.29 | 13.89 | 8.24 | 6.42 | 13.42 | 0.77 | 7.14 | 12.21 | 1.57 |
| Operating Profit | 0.24 | 0.19 | -0.04 | 0.31 | 0.12 | 0.31 | 0.11 | 0.01 | 0.12 | 0.09 | 0.43 | 0.14 | 0.10 |
| OPM % | 1.38% | 3.78% | -0.26% | 3.67% | 4.98% | 2.18% | 1.32% | 0.16% | 0.89% | 10.47% | 5.68% | 1.13% | 5.99% |
| Other Income + | 0.03 | 0.03 | 0.41 | 0.03 | 0.02 | 0.02 | 0.24 | 2.83 | 0.06 | 0.08 | 0.11 | 0.06 | 0.13 |
| Interest | 0.01 | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Depreciation | 0.11 | 0.11 | 0.08 | 0.10 | 0.10 | 0.10 | 0.08 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
| Profit before tax | 0.15 | 0.11 | 0.27 | 0.23 | 0.03 | 0.22 | 0.26 | 2.76 | 0.11 | 0.10 | 0.47 | 0.13 | 0.15 |
| Tax % | 20.00% | 18.18% | 11.11% | 26.09% | 33.33% | 27.27% | 23.08% | 12.68% | 27.27% | 30.00% | 55.32% | 23.08% | 26.67% |
| Net Profit + | 0.12 | 0.09 | 0.25 | 0.17 | 0.02 | 0.16 | 0.20 | 2.41 | 0.08 | 0.08 | 0.21 | 0.11 | 0.12 |
| EPS in Rs | 0.07 | 0.06 | 0.15 | 0.10 | 0.01 | 0.10 | 0.12 | 1.48 | 0.05 | 0.05 | 0.13 | 0.07 | 0.07 |
Financials of Biofil Chemicals
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 5.86 | 13.17 | 13.45 | 12.36 | 23.13 | 29.69 | 35.75 | 22.38 | 30.04 | 40.04 | 33.40 | 28.40 | 22.45 |
| Sales growth | -18.27% | +124.74% | +2.13% | -8.10% | +87.14% | +28.36% | +20.41% | -37.40% | +34.23% | +33.29% | -16.58% | -14.97% | -47.20% |
| Expenses + | 5.12 | 12.30 | 10.84 | 11.43 | 22.11 | 27.87 | 34.15 | 21.05 | 28.88 | 39.23 | 32.55 | 27.75 | 21.69 |
| Operating Profit | 0.74 | 0.87 | 2.61 | 0.93 | 1.02 | 1.82 | 1.60 | 1.33 | 1.16 | 0.81 | 0.85 | 0.65 | 0.76 |
| OPM % | 12.63% | 6.61% | 19.41% | 7.52% | 4.41% | 6.13% | 4.48% | 5.94% | 3.86% | 2.02% | 2.54% | 2.29% | 3.39% |
| Other Income + | 0.46 | 0.53 | 0.14 | 0.10 | 0.10 | 0.17 | 0.80 | 0.15 | 0.10 | 0.49 | 0.31 | 3.08 | 0.38 |
| Interest | 0.21 | 0.15 | 0.16 | 0.15 | 0.16 | 0.12 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.01 | 0.01 |
| Depreciation | 0.25 | 0.26 | 0.28 | 0.30 | 0.37 | 0.41 | 0.41 | 0.43 | 0.43 | 0.40 | 0.38 | 0.27 | 0.28 |
| Profit before tax | 0.74 | 0.99 | 2.31 | 0.58 | 0.59 | 1.46 | 1.92 | 1.01 | 0.79 | 0.86 | 0.74 | 3.45 | 0.85 |
| Tax % | 20.27% | 20.20% | 22.51% | 20.69% | 20.34% | 17.81% | 34.90% | 31.68% | 29.11% | 17.44% | 24.32% | 19.13% | |
| Net Profit + | 0.59 | 0.78 | 1.79 | 0.47 | 0.48 | 1.21 | 1.24 | 0.70 | 0.56 | 0.71 | 0.56 | 2.79 | 0.52 |
| EPS in Rs | 0.36 | 0.48 | 1.10 | 0.29 | 0.29 | 0.74 | 0.76 | 0.43 | 0.34 | 0.44 | 0.34 | 1.71 | 0.32 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Biofil Chemicals
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
| Reserves | -7.86 | -5.37 | -3.58 | -3.11 | -2.62 | -1.39 | -0.14 | 0.56 | 1.03 | 1.93 | 2.51 | 5.29 | 5.51 |
| Borrowings + | 2.98 | 1.37 | 1.43 | 1.56 | 1.64 | 1.19 | 0.43 | 0.46 | 0.52 | 0.44 | 0.47 | 3.02 | 2.17 |
| Other Liabilities + | 2.36 | 11.87 | 7.72 | 9.44 | 8.93 | 26.30 | 16.68 | 1.44 | 13.58 | 28.44 | 31.70 | 18.26 | 29.37 |
| Total Liabilities | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 | 42.84 | 53.32 |
| Fixed Assets + | 9.06 | 8.98 | 9.16 | 9.25 | 10.29 | 10.09 | 9.78 | 9.42 | 9.00 | 8.62 | 8.34 | 6.94 | 6.89 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets + | 4.69 | 15.16 | 12.68 | 14.91 | 13.93 | 32.28 | 23.46 | 9.31 | 22.40 | 38.46 | 42.61 | 35.90 | 46.43 |
| Total Assets | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.95 | 42.84 | 53.32 |
Financials of Biofil Chemicals
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0.01 | 0.14 | 0.71 | 0.46 | 1.26 | 0.89 | 1.11 | -0.22 | -0.11 | 2.39 | -1.92 | -0.60 |
| Cash from Investing Activity + | -0.17 | -0.19 | -0.48 | -0.38 | -1.41 | -0.21 | -0.10 | -0.07 | -0.01 | -0.02 | -0.10 | 1.14 |
| Cash from Financing Activity + | 0.11 | 0.10 | -0.11 | -0.02 | -0.08 | -0.57 | -0.83 | -0.01 | 0.02 | -0.12 | 0.00 | 2.54 |
| Net Cash Flow | -0.05 | 0.05 | 0.13 | 0.06 | -0.24 | 0.12 | 0.18 | -0.30 | -0.11 | 2.25 | -2.03 | 3.07 |
| Free Cash Flow | -0.16 | -0.05 | 0.23 | 0.08 | -0.15 | 0.68 | 1.01 | -0.29 | -0.12 | 2.37 | -2.02 | 0.54 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 19% | 33% | 35% | 103% | 134% | 63% | 112% | 8% | 10% | 314% | -205% | 9% |
Financials of Biofil Chemicals
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 227.35 | 387.45 | 311.00 | 383.31 | 189.84 | 365.25 | 175.81 | 116.94 | 249.08 | 301.10 | 418.77 | 354.59 |
| Inventory Days | 15.99 | 3.46 | 7.29 | 38.11 | 21.73 | 24.37 | 48.85 | 24.20 | 16.11 | 24.81 | 39.52 | 56.24 |
| Days Payable | 198.49 | 400.98 | 304.52 | 341.46 | 156.66 | 373.80 | 178.39 | 11.25 | 168.39 | 268.08 | 366.66 | 239.87 |
| Cash Conversion Cycle | 44.85 | -10.07 | 13.76 | 79.95 | 54.90 | 15.82 | 46.27 | 129.88 | 96.80 | 57.83 | 91.63 | 170.96 |
| Working Capital Days | -47.96 | 48.50 | 87.65 | 104.83 | 50.81 | 55.69 | 64.12 | 125.25 | 104.25 | 69.37 | 114.09 | 152.17 |
| ROCE % | 8.59% | 9.64% | 18.72% | 5.06% | 5.00% | 10.08% | 12.20% | 6.20% | 4.73% | 4.94% | 4.12% | 2.97% |
Biofil Chemicals & Pharmaceuticals: frequently asked questions
What is Biofil Chemicals & Pharmaceuticals share price today?
Biofil Chemicals & Pharmaceuticals last traded at ₹31.39, with a market capitalisation of ₹51 Cr and a P/E ratio of 98.2.
What were Biofil Chemicals & Pharmaceuticals's latest quarterly results?
For the quarter ended Sep 2026, Biofil Chemicals & Pharmaceuticals reported revenue of ₹2 Cr (-87.67% year on year) and net profit of ₹0 Cr, with an operating margin of 5.99%.
Is Biofil Chemicals & Pharmaceuticals's profit growing?
Net profit was ₹0 Cr in Sep 2026 against ₹0 Cr in Sep 2025, a change of +50%.
What is Biofil Chemicals & Pharmaceuticals's EPS?
Biofil Chemicals & Pharmaceuticals's earnings per share for the quarter ended Sep 2026 was ₹0.07.
What is the promoter holding in Biofil Chemicals & Pharmaceuticals?
Promoters held 46.79% of Biofil Chemicals & Pharmaceuticals in Sep 2026 (unchanged versus Jun 2026).
How much do FIIs and DIIs hold in Biofil Chemicals & Pharmaceuticals?
In Sep 2026, foreign institutional investors held 0.00% and domestic institutions (including mutual funds) held 0.08% of Biofil Chemicals & Pharmaceuticals.
What is Biofil Chemicals & Pharmaceuticals's ROE and ROCE?
Biofil Chemicals & Pharmaceuticals's return on equity is -2.83% and its return on capital employed is 2.97%.
Does Biofil Chemicals & Pharmaceuticals pay a dividend?
Biofil Chemicals & Pharmaceuticals's dividend yield is 0% at the current price; see the Biofil Chemicals & Pharmaceuticals dividends page for past payouts.
Which sector does Biofil Chemicals & Pharmaceuticals belong to?
Biofil Chemicals & Pharmaceuticals is in the Pharmaceuticals & Biotechnology sector. Its peer comparison and sector ranking are on this page.
What did Biofil Chemicals & Pharmaceuticals's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Biofil Chemicals & Pharmaceuticals's management.
How does Arthneeti AI analyse Biofil Chemicals & Pharmaceuticals?
Arthneeti reads Biofil Chemicals & Pharmaceuticals's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Biofil Chemicals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Alpa Laboratorie (Q2 FY27)
Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Aarey Drugs (Q2 FY27)
Revenue from Operations for quarter ended 30.09.2026: ₹2,865.24 Lakhs . Key results statement takeaways from Aarey Drugs & Pharmaceuticals Ltd's Q2 FY27 results
